Goldman Sachs’s Travere Therapeutics TVTX Stock Holding History

Goldman Sachs’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-1,700	Closed	-$36K	–	6407
2017 Q4	$36K	Hold	1,700	–	–	﹤0.01%	6008
2017 Q3	$42K	Sell	1,700 -500	-23%	-$11K	﹤0.01%	6293
2017 Q2	$43K	Buy	2,200 +500	+29%	+$9.07K	﹤0.01%	6390
2017 Q1	$31K	Sell	1,700 -2,100	-55%	-$41.1K	﹤0.01%	6411
2016 Q4	$72K	Sell	3,800 -1,300	-25%	-$26.6K	﹤0.01%	6280
2016 Q3	$114K	Sell	5,100 -985,400	-99%	-$18.8M	﹤0.01%	6163
2016 Q2	$17.6M	Sell	990,500 -219,200	-18%	-$3.55M	0.01%	1879
2016 Q1	$16.5M	Sell	1,209,700 -32,300	-3%	-$490K	0.01%	1857
2015 Q4	$24M	Sell	1,242,000 -218,200	-15%	-$4.36M	0.01%	1630
2015 Q3	$29.6M	Buy	+1,460,200	New	+$43.3M	0.01%	1425

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Goldman Sachs's TVTX Position: Q1 2026 in Review

Goldman Sachs reduced its Travere Therapeutics (TVTX) stake by 7.9% in Q1 2026, selling an estimated $4.44M and leaving 1,719,721 shares worth $51.1M. The position accounts for 0.01% of the portfolio, ranked #1567.

Goldman Sachs first reported a position in TVTX in Q3 2014 and has held it in 47 quarters since. The position peaked at $80.5M in Q4 2021. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

Goldman Sachs held 1,719,721 shares of Travere Therapeutics worth $51.1M as of Q1 2026.
Goldman Sachs sold 148,491 Travere Therapeutics shares in Q1 2026, an estimated $4.44M.
Travere Therapeutics made up 0.01% of Goldman Sachs's portfolio in Q1 2026, its #1567 holding.
Goldman Sachs first reported a position in Travere Therapeutics in Q3 2014 and has held it in 47 quarters since.
Goldman Sachs's Travere Therapeutics position peaked at $80.5M in Q4 2021.
260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.